Effect of glipizide GITS on insulin sensitivity, glycemic indices, and abdominal fat composition in NIDDM

Drug Development Research

Volumn 44, Issue 1, 1998, Pages 1-7

  Cefalu, William T ^a,b   Bell Farrow, Audrey ^a   Wang, Zhong Q ^a   McBride, Debra ^a   Dalgleish, Debra ^a   Terry, James G ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF VERMONT   (United States)

Author keywords

Diabetes; Glucose; Insulin; Sulfonylurea

Indexed keywords

FRUCTOSAMINE; GLIPIZIDE; GLYCOSYLATED HEMOGLOBIN; ORAL ANTIDIABETIC AGENT; PLACEBO;

ADULT; AGED; ARTICLE; BODY WEIGHT; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG DELIVERY SYSTEM; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE TEST; HUMAN; HUMAN TISSUE; INSULIN SENSITIVITY; LIPID COMPOSITION; LIPID STORAGE; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; NUCLEAR MAGNETIC RESONANCE IMAGING; ORAL DRUG ADMINISTRATION; RANDOMIZED CONTROLLED TRIAL;

EID: 0031851270     PISSN: 02724391     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1098-2299(199805)44:1<1::AID-DDR1>3.0.CO;2-L     Document Type: Article

References (36)

1. ADA (American Diabetes Association) (1995): Consensus statement: The pharmacological treatment of hyperglycemia in NIDDM. Diabetes Care 18(11):1510-1508.
2. Beck-Nielsen H, Hother-Nielsen O, Pedersen O (1988): Mechanism of action of sulphonylureas with special reference to the extrapancreatic effect: An overview. Diabet Med 5:613-620.
3. Berelowitz M, Fischette C, Cefalu W, Schade D, Sutfin T, Kourides IA (1994): Comparative efficacy of a once-daily controlled-release formulation of glipizide and immediate-release glipizide in patients with NIDDM. Diabetes Care 17(12):1460-1464.
4. Berelowitz M, Go E, Brook S (1996): Contrasting influences of glipizide GITS and glyburide on fasting and post sustacal glycemia, glucose production and 24h glucose/insulin profiles in NIDDM. Diabetes 45(2):285a.
5. Burge MR, Schmitz K, Tive L, Schade DS (1996): Epinephrine is the mechanism of protection against sulfonylurea-induced hypoglycemia in fasted NIDDM patients. Diabetes 45(2):61A.
6. Cefalu WT, Bell-Farrow AD, Petty M, Izlar C (1991): Clinical validation of a new, 2nd generation fructosamine assay. Clin Chem 37(7):1252-1256.
7. Cefalu WT, Wang ZQ, Bell-Farrow AD, Kiger FD, Izlar C (1994): Glycohemoglobin measured by automated affinity HPLC correlates with both short-term and long-term antecedent glycemia. Clin Chem 40(7):1317-1321.
8. Cefalu WT, Wang ZQ, Werbel SA, Bell-Farrow A, Crouse JR III, Hinson WH, Terry JG, Anderson R (1995): Contribution of visceral fat mass to the insulin resistance of aging. Metabolism 44:954-959.
9. Clarke BF, Campbell IW (1977): Comparison of metformin and chlorpropamide in non obese, maturity-onset diabetics uncontrolled by diet. Br Med J ii:1576-1578.
10. Coon PJ, Rogus EM, Drinkwater D, Muller DC, Goldberg AP (1992): Role of body fat distribution in the decline in insulin sensitivity and glucose tolerance with age. J. Clin Endocrinol Metab 75:1125-1132.
11. Defronzo RA, Ferrannini E (1991): Insulin resistance: A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care 14:173-194.
12. Finegood DT, Hramiak IM, Dupre J (1990): A modified protocol for estimation of insulin sensitivity with the minimal model of glucose kinetics in patients with insulin-dependent diabetes. J Clin Endocrinol Metab 70:1538-1549.
13. Folsom AR, Burke GL, Ballew C, Jacobs DR, Haskell WL et al. (1989): Relation of body fatness and its distribution to cardiovascular risk factors in young black and whites. The role of insulin. Am J Epidemiol 130:911-924.
14. Fontbonne AM, Eschwège EM (1991): Insulin and cardiovascular disease, Paris Prospective Study. Diabetes Care 14:461-469.
15. Fowler LK (1978): Glipizide in the treatment of maturity-onset diabetes: A multi-centre, out-patient study. Curr Med Res Opin 5(5):418-423.
16. Gavin JR III (1985): Dual actions of sulfonylureas and glyburide: Receptor and post-receptor effects. Am J Med 79(3B):34-42.
17. Gerich JE (1989): Oral hypoglycemic agents. N Engl J Med 321: 1231-1245.
18. Gillum RF (1987): The association of body fat distribution with hypertension, hypertensive heart disease, coronary heart disease, diabetes and cardiovascular risk factors in men and women aged 18-79 years. J Chron Dis 40:421-428.
19. Groop LC (1992): Sulfonylureas in NIDDM. Diabetes Care 15(6): 737-754.
20. Howard G, O'Leary DH, Zaccaro D et al. (1996): The Insulin Resistance Atherosclerosis Study (IRAS). Circulation 93(10):1809-1817.
21. Haffner SM, Fong D, Hazuda HP, Pugh JA, Patterson JK (1988): Hyperinsulinemia, upper body adiposity and cardiovascular risk factors in non-diabetics. Metabolism 37:338-345.
22. Hirshman MF, Horton ES (1990): Glyburide increases insulin sensitivity and responsiveness in peripheral tissues of the rat as determined by the glucose clamp technique. Endocrinology 126:2407-2412.
23. Johnson AB, Argyraki M, Thow JC, Jones IR, Broughton D, Miller M, Taylor R (1991): The effect of sulphonylurea therapy on skeletal muscle glycogen synthase activity and insulin secretion in newly presenting type 2 (non-insulin dependent) diabetic patients. Diabet Med 8:243-253.
24. Kohrt WM, Kirwan JP, Staten MA, Bourey RE, King DS (1993): Insulin resistance in aging is related to abdominal obesity. Diabetes 42:273-281.
25. Malaisse WJ, Lebrun P (1990): Mechanisms of sulfonylurea-induced insulin release. Diabetes Care 13(3):9-17.
26. Pedersen O, Hother-Nielsen O, Bak J, Hjollund E, Beck-Nielsen H (1991): Effects of sulfonylureas on adipocyte and skeletal muscle insulin action in patients with non-insulin-dependent diabetes mellitus. Am J Med 90(6A):22-28.
27. Pyörälä K, Uusitupa M, Laakso M, Siitonen O, Niskanen L, Ronnemaa T (1987): Macrovascular complications in relation to hyperinsulinemia in non-insulin-dependent diabetes mellitus. Diabetes Metab 13:345-349.
28. Robb GH, Lowe SM (1984): Lack of weight gain with gliclazide treatment for 30 months in type II diabetes. Curr Med Res Opin 9(1):7-9.
29. Rossetti L, Giaccari A, DeFronzo RA (1990): Glucose toxicity. Diabetes Care 13:610-630.
30. Shaw KM, Wheeley MS, Campbell DB, Ward JD (1985): Home blood glucose monitoring in non-insulin-dependent diabetics: The effect of gliclazide on blood glucose and weight control, a multicentre trial. Diabet Med 2(6):484-490.
31. Simonson DC, Ferrannini E, Bevilacqua S, Smith D, Barrett E, Carlson R. DeFronzo RA (1984): Mechanism of improvement in glucose metabolism after chronic glyburide therapy. Diabetes 33:838-845.
32. Simonson DC, Kourides IA, Feinglos M, Shamoon H, Fischette CT (1997): The Glipizide Gastrointestinal Therapeutic System Study Group. Efficacy, safety, and dose-response characteristics of glipizide gastrointestinal therapeutic system on glycemic control and insulin secretion in NIDDM. Diabetes Care 20(4):597-606.
33. Stout RW (1990): Insulin and atheroma: 20-yr perspective. Diabetes Care 13:631-654.
34. UKPDS (United Kingdom Prospective Diabetes Study) (1995): 13: Relative efficacy of randomly allocated diet, sulfonylurea, insulin, or metformin in patients with newly diagnosed non-insulin dependent diabetes followed for three years. Br Med J 310(6972):83-88.
35. Welch S, Gebhart SSP, Bergman RN, Phillips LS (1990): Minimal model analysis of intravenous glucose tolerance test-derived insulin sensitivity in diabetes subjects. J Clin Endocrinol Metab 71:1508-1518.
36. Zurro HJ, Lavielle R (1986): Is sulfonylurea therapy effective long term? A 3-year study with gliclazide. Curr Med Res Opin 10(5):351-358.